Epidemiological cutoff values for azoles and Aspergillus fumigatus based on a novel mathematical approach incorporating cyp51A sequence analysis

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 5, 2012, Pages 2524-2529

  Meletiadis, J ^a   Mavridou, E ^b   Melchers, W J G ^b   Mouton, J W ^b,c   Verweij, P E ^b  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c CANISIUS WILHELMINA HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ITRACONAZOLE; POSACONAZOLE; VORICONAZOLE;

ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; CONTROLLED STUDY; CYP51A GENE; FUNGAL GENE; FUNGAL GENETICS; GENE MUTATION; GENETIC CODE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; REFERENCE VALUE; SEQUENCE ANALYSIS;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG RESISTANCE, FUNGAL; FUNGAL PROTEINS; HUMANS; ITRACONAZOLE; LONGITUDINAL STUDIES; MATHEMATICAL COMPUTING; MICROBIAL SENSITIVITY TESTS; MODELS, STATISTICAL; MUTATION; NETHERLANDS; PROMOTER REGIONS, GENETIC; PYRIMIDINES; SEQUENCE ANALYSIS, DNA; TANDEM REPEAT SEQUENCES; TRIAZOLES;

EID: 84860192616     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05959-11     Document Type: Article

References (33)

1. Altman DG. 1999. Practical statistics for medical research, p 132-143. Chapman & Hall, London, United Kingdom.
2. Arendrup MC, et al. 2010. Development of azole resistance in Aspergillus fumigatus during azole therapy associated with change in virulence. PLoS One 5:e10080.
3. Bueid A, et al. 2010. Azole antifungal resistance in Aspergillus fumigatus: 2008 and 2009. J. Antimicrob. Chemother. 65:2116 -2118.
4. Camps SMT, et al. 2012. Rapid induction of multiple resistance mechanisms in Aspergillus fumigatus during azole therapy: a case study and review of the literature. Antimicrob. Agents Chemother. 56:10 -16.
5. CLSI. 2008. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard - second edition. CLSI document M38-A2. Clinical and Laboratory Standards Institute, Wayne, PA.
6. Dannaoui E, et al. 2001. Acquired itraconazole resistance in Aspergillus fumigatus. J. Antimicrob. Chemother. 47:333-340. (Pubitemid 32229575)
7. Denning DW, et al. 1997. Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigatus infection. J. Antimicrob. Chemother. 40:401- 414.
8. de Valk HA, et al. 2005. Use of a novel panel of nine short tandem repeats for exact and high-resolution fingerprinting of Aspergillus fumigatus isolates. J. Clin. Microbiol. 43:4112- 4120.
9. Espinel-Ingroff A, et al. 2010. Wild-type MIC distributions and epidemiological cutoff values for the triazoles and six Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). J. Clin. Microbiol. 48:3251-3257.
10. Espinel-Ingroff A, et al. 2011. Wild-type MIC distributions and epidemiological cutoff values for caspofungin and Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). Antimicrob. Agents Chemother. 55:2855-2859.
11. EUCAST. 2011. Itraconazole and Aspergillus spp. Rationale for the EUCAST clinical breakpoints, version 1.0. http://www.eucast.org/fileadmin/src/media /PDFs/EUCAST-files/Rationale-documents/Itraconazole-Aspergillus-v1-0f .pdf.
12. EUCAST. 2008. EUCAST technical note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia-forming moulds. Clin. Microbiol. Infect. 14:982-984.
13. EUCAST. 2011. Posaconazole and Aspergillus spp. Rationale for the EUCAST clinical breakpoints, version 1.0. http://www.eucast.org/fileadmin/src /media/PDFs/EUCAST-files/Rationale-documents/Posaconazole-Aspergillus -rationale-1-0f.pdf.
14. Felton TW, et al. 2010. Efficacy and safety of posaconazole for chronic pulmonary aspergillosis. Clin. Infect. Dis. 51:1383-1391.
15. Howard SJ, et al. 2009. Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg. Infect. Dis. 15:1068 -1076.
16. Kuipers S, et al. 2011. Failure of posaconazole therapy in a renal transplant patient with invasive aspergillosis due to Aspergillus fumigatus with attenuated susceptibility to posaconazole. Antimicrob. Agents Chemother. 55:3564 -3566.
17. Mavridou E, Bruggemann RJ, Melchers WJ, Mouton JW, Verweij PE. 2010. Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene. Antimicrob. Agents Chemother. 54:860-865.
18. Mavridou E, Meletiadis J, Bruggemann RJ, Verweij P, Mouton JW. 2010. Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother. http: //www.icaac.org/.
19. Meletiadis J, et al. 2002. In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates. Antimicrob. Agents Chemother. 46:62- 68.
20. Mellado E, Diaz-Guerra TM, Cuenca-Estrella M, Rodriguez-Tudela JL. 2001. Identification of two different 14-alpha sterol demethylase-related genes (cyp51A and cyp51B) in Aspergillus fumigatus and other Aspergillus species. J. Clin. Microbiol. 39:2431-2438. (Pubitemid 32606215)
21. Mellado E, et al. 2007. A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. Antimicrob. Agents Chemother. 51:1897-1904. (Pubitemid 46903071)
22. Murphy M, Bernard EM, Ishimaru T, Armstrong D. 1997. Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis. Antimicrob. Agents Chemother. 41:696-698. (Pubitemid 27098427)
23. Nascimento AM, et al. 2003. Multiple resistance mechanisms among Aspergillus fumigatus mutants with high-level resistance to itraconazole. Antimicrob. Agents Chemother. 47:1719 -1726.
24. Pascual A, et al. 2008. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin. Infect. Dis. 46:201-211. (Pubitemid 351269158)
25. Pfaller MA, et al. 2009. Wild-type MIC distribution and epidemiological cutoff values for Aspergillus fumigatus and three triazoles as determined by the Clinical and Laboratory Standards Institute broth microdilution methods. J. Clin. Microbiol. 47:3142-3146.
26. Rodriguez-Tudela JL, et al. 2008. Epidemiological cutoffs and crossresistance to azole drugs in Aspergillus fumigatus. Antimicrob. Agents Chemother. 52:2468 -2472.
27. Snelders E, Melchers WJ, Verweij PE. 2011. Azole resistance in Aspergillus fumigatus: a new challenge in the management of invasive aspergillosis? Future Microbiol. 6:335-347.
28. Snelders E, et al. 2008. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med. 5:e219.
29. Turnidge J, Kahlmeter G, Kronvall G. 2006. Statistical characterisation of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values. Clin. Microbiol. Infect. 12:418-425.
30. Reference deleted.
31. van der Linden JW, et al. 2011. Clinical implications of azole resistance in Aspergillus fumigatus, the Netherlands, 2007-2009. Emerg. Infect. Dis. 17:1846 -1854.
32. Verweij PE, Howard SJ, Melchers WJ, Denning DW. 2009. Azoleresistance in Aspergillus: proposed nomenclature and breakpoints. Drug Resist. Updat. 12:141-147.
33. Verweij PE, Mellado E, Melchers WJ. 2007. Multiple-triazole-resistant aspergillosis. N. Engl. J. Med. 356:1481-1483.